Detail akcie Evaxion Bio Sp ADS online

Business Summary: Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Evaxion A/S (ADR) revenues increased from $3.2M to $7.5M. Net loss applicable to common stockholders decreased 74% to $1.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Change in fair value of derivative liabi decrease of 60% to $654K (expense), Research and development decrease of 10% to $7.4M (expense).